Every story in this section, newest first — page 43 of 373.
Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.
BeyondSpring (NASDAQ:BYSI) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Plinabulin in combination with docetaxel for previously treated advanced non-squamous lung cancer.
BIO-key (NASDAQ:BKYI) announced a partnership with Al Majlis Group to introduce its identity security platform to organizations in the United Arab Emirates and Saudi Arabia.
Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.
Turbo Energy (NASDAQ:TURB) reported first-half 2026 financial results, with significant revenue growth and a return to profitability.
Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.
Caterpillar (NYSE:CAT) announced an agreement to acquire John Fabick Tractor Company, an independent Cat dealer serving customers across parts of the Midwest United States.
PowerBank (NASDAQ:PBK) reported fiscal 2026 financial results, with lower revenue but improved gross margins and a narrower net loss.
SLB (NYSE:SLB) announced that its OneSubsea joint venture has been awarded a contract by ExxonMobil Moçambique, Limitada, on behalf of its Area 4 partners, to deliver subsea production systems for the first phase of the offshore Rovuma LNG project in Mozambique.
Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.
Unicycive Therapeutics (NASDAQ:UNCY) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in patients receiving dialysis.
uniQure (NASDAQ:QURE) reported additional Phase I/II data for ifezuntirgene inilparvovec, its investigational gene therapy for Huntington’s disease, with follow-up results extending to 36 and 48 months.
Invivyd (NASDAQ:IVVD) reported Phase 3 LIBERTY trial results showing that its investigational COVID-19 antibody product VYD2311 demonstrated fewer reported adverse events compared with an mRNA COVID-19 vaccine.
IM Cannabis (NASDAQ:IMCC) completed the sale of IMC Holdings to Slil, following a transaction that included a previously paid C$3 million payment as part of the consideration.
Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Zepbound 10 mg and 15 mg were associated with greater weight loss than Wegovy HD 7.2 mg in adults with obesity.
Scholastic (NASDAQ:SCHL) signed a definitive agreement to acquire Cottage Door Press for approximately $71 million, subject to customary purchase price adjustments.
Scorpio Tankers (NYSE:STNG) announced agreements to sell three product tankers and acquire four newbuilding vessels as part of its fleet management strategy.
Parsons (NYSE:PSN) won an initial $85 million agreement to provide advisory services for the development of the U.S. Space Command’s new headquarters at Redstone Arsenal in Alabama.
GFL Environmental (NYSE:GFL) declared a third-quarter 2026 cash dividend of US$0.0169 per subordinate and multiple voting share.
Westlake (NYSE:WLK) announced plans to close its PVC manufacturing facility in Cologne, Germany, during the first quarter of 2027 as part of efforts to improve profitability in its European chlorovinyl operations.
Amcor (NYSE:AMCR) announced that Board Chair Graeme Liebelt will retire from the company’s board, with Tom Long set to succeed him following the annual meeting on November 11, 2026.
iHuman (NYSE:IH) reported second-quarter 2026 financial results, with revenue and user numbers declining while the company moved to a net loss compared with the prior-year period.
CarMax (NYSE:KMX) reported results for the second quarter ended August 31, 2026, with higher vehicle sales, revenue growth, and improved earnings.
Kura Oncology (NASDAQ:KURA) and Caspian Therapeutics presented preclinical findings for KO-7246, an investigational diabetes treatment candidate, at the European Association for the Study of Diabetes (EASD) meeting in Milan.
